Market Analysis: June 7th, 2025
Canadian Markets
Canada's TSX dropped slightly on Monday, as geopolitical tensions and trade uncertainties prompted investors to step back from riskier assets. With limited domestic catalysts, traders remained cautious, particularly amid developments in global trade policy and renewed tensions between major economies. Concerns around global tariffs and U.S. trade maneuvering contributed to a risk-off sentiment, weighing on sectors tied to global growth.
American Markets
American stocks also declined, dragged lower by a resurgence in trade concerns. The uncertainty added to recent market volatility, keeping gains in check and influencing trading sentiment worldwide, as traders and Investors flocked to the US dollar to mitigate risk. The Federal Reserve announced that the U.S. economy may still return to near-zero interest rates in the future, despite the recent cycle of aggressive rate hikes aimed at combating inflation. .
European Markets
European shares moved higher, buoyed by strength in the technology and banking sectors. The optimism was further supported by data showing Eurozone investor morale had reached a three-year high, a sign that the economic recovery is expanding more broadly across the region. Despite the shadow of U.S. trade tensions, European markets appeared relatively resilient, focusing instead on domestic economic momentum and improved earnings outlooks for several sectors.
UK markets fell lower by energy heavyweight Shell Plc, as the oil and gas major warned that its second-quarter results would likely disappoint, citing weaker performance in its historically strong oil and gas trading division. That news, combined with broader concerns about the impact of U.S. tariffs on global demand, dragged down stocks while UK house prices stagnated as mortgage rates remain elevated.
Corporate News
Alphabet Inc (Google) Google faces an EU antitrust complaint over its AI Overviews, accused of misusing publisher content and causing losses in traffic and ad revenue. Independent publishers are seeking interim measures from the European Commission.
Apple Inc Apple is appealing a €500 million EU fine related to App Store practices. The company argues the European Commission's mandates are confusing and anti-competitive, stating it complied only to avoid further penalties.
Birkenstock Holding PLC Indian authorities seized counterfeit Birkenstock shoes after the company filed a trademark infringement lawsuit in the Delhi High Court. The counterfeits were reportedly produced around Agra and sold domestically and abroad.
BlackRock Inc Jio BlackRock Asset Management raised over $2.1 billion in its first mutual fund launch since getting licensed in May, attracting over 90 institutional and 67,000+ retail investors.
Boeing Co Boeing secured a $2.8 billion contract for two strategic communication satellites, with options for two more. The company also announced CFO Jay Malave's compensation package, including a $1.05M salary and performance bonuses.
Constellation Brands Inc Jefferies upgraded to Buy from Hold and raised the target price to $205 from $194, expecting a rebound in growth and stronger free cash flow in H2 2025.
Ero Copper Corp BMO raised its price target to C$27 from C$24, anticipating the Tucumã project will drive copper output and free cash flow generation.
General Electric Co (GE Aerospace) The U.S. government allowed GE to resume jet engine exports to China's COMAC, lifting prior suspensions and easing U.S.-China trade tensions.
Mondelez International Inc The company is calling for a one-year delay to the EU's deforestation law, warning of disruptions in cocoa supply chains due to high costs and infrastructure issues in producing countries.
Netflix Inc Seaport Research downgraded to Neutral from Buy, citing the need for more time to meet high market expectations amid increased competition and strategic shifts.
Phibro Animal Health Corp JPMorgan upgraded to Overweight from Neutral, noting strong demand and pricing power as key drivers for continued revenue growth.
SanDisk Corp Jefferies initiated coverage with a Buy rating and $60 target, forecasting gains in eSSD market share due to the company's technology roadmap.
Shell PLC Shell expects Q2 earnings to fall, citing weak results in its integrated gas and chemicals divisions, and revealed a $200 million exploration write-off.
Taiwan Semiconductor Manufacturing Co (TSMC) TSMC may delay a Japan chip plant to focus on its U.S. operations in response to tariff concerns. The company insists its global investment strategy remains intact.
Tesla Inc Shares declined amid renewed concerns over CEO Elon Musk's political distractions. Meanwhile, UK Tesla sales increased in June, helped by deliveries of the updated Model Y.
Yum! Brands Inc Yum! is in talks to merge Indian franchisees Devyani International and Sapphire Foods via a share swap, potentially offering 1 Devyani share for every 3 Sapphire shares.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
7 minutes ago
- Globe and Mail
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry 's decline of 2.2%. The stock has also outperformed the sector and the S&P 500 index in this time frame. Gilead Outperforms Industry, Sector & S&P 500 Index It has been an eventful year for GILD so far. The company recently obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV. This groundbreaking injectable therapy marks the first and only twice-yearly pre-exposure prophylaxis (PrEP) option available in the United States. Let's delve further into GILD's strengths and weaknesses to analyze how to play the stock at present. Lenacapavir Approval Boosts GILD's HIV Franchise Gilead has a market-leading portfolio of HIV treatments. Flagship drug Biktarvy accounts for over 51% share of the treatment market in the United States and should maintain momentum. Descovy (FTC 200 mg/TAF 25 mg) for PrEP is also witnessing good uptake. It maintains over 40% market share in the PrEP market in the United States. The recent FDA approval of lenacapavir under the brand name Yeztugo solidifies GILD's HIV portfolio as its other prevention drug, Truvada, faces generic competition. At present, there are two FDA-approved daily oral medications for PrEP — Truvada and Descovy. As the first long-acting injectable PrEP administered just twice a year, Yeztugo addresses persistent barriers, such as challenges with daily oral PrEP, adherence, stigma and healthcare access, which have limited broader PrEP adoption. This approval also represents a paradigm shift in HIV prevention and is expected to catalyze uptake among populations that have historically been underserved by existing prevention tools. Yeztugo has a competitive advantage as it needs to be taken only twice a year, unlike daily oral pills, and addresses a broad population. The European Medicines Agency has also validated the Marketing Authorization Application for twice-yearly lenacapavir for HIV prevention. Livdelzi Strengthens GILD's Liver Disease Portfolio GILD's diverse portfolio also includes drugs for liver, hematology/oncology and inflammation/respiratory diseases. The FDA approval of seladelpar for the treatment of primary biliary cholangitis (PBC) has strengthened GILD's liver disease portfolio and validated its CymaBay acquisition. The drug's initial uptake is encouraging. The candidate was approved under the brand name Livdelzi. Gilead also recently received conditional marketing authorization from the European Commission for seladelpar for the treatment of PBC. Challenges for GILD's Oncology Business Gilead's oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified its overall business. However, the Cell Therapy franchise, comprising Yescarta and Tecartus, is currently under pressure due to competitive headwinds in the United States and Europe that are expected to continue in 2025. Breast cancer drug Trodelvy's sales were lower than expected in the first quarter due to inventory dynamics. Nonetheless, Gilead announced positive top-line results from the phase III ASCENT-03 study on Trodelvy, which showed highly statistically significant and clinically meaningful improvement in progression-free survival in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not candidates for checkpoint inhibitors. The potential launch of anito-cel in multiple myeloma and Trodelvy in first-line mTNBC in 2026 will strengthen the company's oncology business. GILD's Valuation and Estimate Revision According to the price/earnings ratio, GILD's shares currently trade at 13.62x forward earnings, lower than the large-cap pharma industry's average of 15.01X but higher than its mean of 10.52X. Earnings estimates for GILD have moved north in the past 60 days. The bottom-line estimate for 2025 has inched up to $7.92 from $7.91, while that for 2026 has improved to $8.48 from $8.39. Invest in GILD Large biotech companies are generally considered safe havens for investors interested in this sector as they are well-equipped to weather the uncertain macroenvironment. Gilead's efforts to constantly innovate its HIV portfolio should enable it to maintain growth amid competition from GSK plc GSK. The approval of Yeztugo for PrEP is a major boost for the company. GSK's HIV portfolio sales are being driven by strong patient demand for Cabenuva, Apretude and Dovato. GILD has also collaborated with Merck MRK to evaluate the investigational combination of islatravir and lenacapavir for the treatment of HIV. Gilead's strategic deals and acquisitions to diversify its business are encouraging. We recommend the stock to prospective investors, as we believe there is more room for growth following Yeztugo approval, even though Biktarvy sales are expected to be under pressure due to the redesign of Medicare Part D. Another positive factor for both prospective and existing investors is the company's attractive dividend yield. Gilead has been consistently increasing and paying out dividends. The company declared a quarterly dividend of $0.79 per share of common stock for the second quarter of 2025. Its strong cash position (as of March 31, 2025, GILD had $7.9 billion of cash, cash equivalents and marketable debt securities) indicates that the current yield of 2.83% is sustainable. Gilead presently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Globe and Mail
7 minutes ago
- Globe and Mail
ZA Miner Goes Mainstream with New Contracts, Mobile App, and Rock-Solid Security
London, UK – July 8, 2025 — ZA Miner is making headlines this week as it officially rolls out its most flexible contracts yet, an enhanced affiliate program, and a slick new mobile app—all while leaning hard into security and sustainability. Fresh Contracts, Daily Payouts, and a $100 Test Drive Back in June, ZA Miner launched a range of updated mining packages from 1 to 16 days, starting at just $100. These new short‑term contracts promise stable, daily returns—historic figures showing up to ~2 % per day on some plans. Better yet, new users can sign up with a $100 trial bonus that begins earning from day one. Why Security Is ZA Miner's Cornerstone ZA Miner's growing popularity isn't just about attractive returns—it's their security setup that's drawing attention. Here's a snapshot of why users feel safe: Enterprise-grade SSL encryption and full DDoS defense —protecting passwords, transactions, and sensitive info Cold‑wallet asset storage ensures user funds stay offline and out of reach Two‑factor login, McAfee®, and Cloudflare® protections bolster the user experience Green Crypto – Powered by the Sun and the Wind Mining often gets flak for being energy‑hungry—but ZA Miner flips that script. Their data centres tap into solar, wind, and even hydroelectric sources across multiple continents. On top of that, the outfit uses high-efficiency NVIDIA and AMD GPUs alongside top-of-the-line ASICs to maximize power vs. electricity use It's cloud mining with a clear conscience. Users Say: It Just Works Reviews and press releases are full of praise: reports that ZA Miner's mobile app 'gives users the power to generate daily cryptocurrency income … with no hardware, no experience, and no interruptions.' One user told 'This platform changed the way I approach investing. I don't need to worry about technical setups or market timing—everything runs in the background.' How Anyone Can Start Getting started is simple: Final Take ZA Miner is staking a strong position with its latest contract rollout, robust security infrastructure, eco‑friendly energy use, and a zero‑hassle mobile experience. For anyone curious about cloud mining but hesitant to deal with rigs, electricity bills or technical headaches, this platform has become a compelling option. Bottom line: With eco-conscious operations, daily payouts, and a smooth mobile experience, ZA Miner is rapidly shaping itself into a trustworthy, user‑friendly gateway into crypto mining. Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks. There is a possibility of financial loss. You are advised to perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor.
Winnipeg Free Press
12 minutes ago
- Winnipeg Free Press
S&P/TSX composite down more than 100 points, U.S. stock markets also head lower
TORONTO – Canada's main stock index fell more than 100 points, weighed down by losses in the technology sector, while U.S. stock markets also fell. The S&P/TSX composite index was down 129.73 points at 26,890.55. In New York, the Dow Jones industrial average was down 147.92 points at 44,258.44. The S&P 500 index was down 7.61 points at 6,222.37, while the Nasdaq composite was down 7.41 points at 20,405.11. The Canadian dollar traded for 73.10 cents US compared with 73.23 cents US on Monday. The August crude oil contract was up 15 cents US at US$68.08 per barrel. The August gold contract was down US$39.70 at US$3,303.10 an ounce. Monday Mornings The latest local business news and a lookahead to the coming week. This report by The Canadian Press was first published July 8, 2025. Companies in this story: (TSX:GSPTSE, TSX:CADUSD)
